Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies

Abstract Tissue kallikrein (KLK1) and the kallikrein-related peptidase (KLK2–15) genes encode for a subgroup of 15 homologous secreted serine proteases possessing numerous physiological roles, such as the regulation of blood pressure, hormone processing and tissue remodeling. The expression of KLKs is detected in a broad spectrum of human tissues where it has been found to be regulated mainly by steroids hormones. The aberrant expression of KLKs, presented in many human malignancies, highlights the significance of this gene family for early diagnosis, prognosis and monitoring of cancer patients, as it is strongly emphasized by the routine use of PSA (KLK3) for prostate cancer management. Here, we review the presently known data regarding the role of KLKs as cancer biomarkers, giving emphasis on novel information about the subject.

[1]  Mohd Fahad Ullah,et al.  The footprints of cancer development: Cancer biomarkers. , 2009, Cancer treatment reviews.

[2]  B. Davidson,et al.  Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. , 2004, Gynecologic oncology.

[3]  G. Yousef,et al.  The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.

[4]  Klaus Jung,et al.  PSA and other tissue kallikreins for prostate cancer detection. , 2007, European journal of cancer.

[5]  A. Scorilas,et al.  Expression analysis and study of KLK4 in benign and malignant breast tumours , 2009, Thrombosis and Haemostasis.

[6]  L. Briollais,et al.  High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis , 2009, Journal of cellular and molecular medicine.

[7]  J. Foekens,et al.  Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer , 1999, British Journal of Cancer.

[8]  E. Diamandis,et al.  The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast , 2004, Breast Cancer Research and Treatment.

[9]  E. Diamandis,et al.  Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. , 2008, Clinical chemistry.

[10]  D. Katsaros,et al.  Human tissue kallikreins: from gene structure to function and clinical applications. , 2005, Advances in clinical chemistry.

[11]  A. Scorilas,et al.  KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone , 2010, Biological chemistry.

[12]  Miltiadis Paliouras,et al.  Human tissue kallikreins: the cancer biomarker family. , 2007, Cancer letters.

[13]  J. Clements,et al.  A comprehensive nomenclature for serine proteases with homology to tissue kallikreins , 2006, Biological chemistry.

[14]  T. Utsunomiya,et al.  Clinical Significance of Human Kallikrein Gene 6 Messenger RNA Expression in Colorectal Cancer , 2005, Clinical Cancer Research.

[15]  H Ballentine Carter,et al.  Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. , 2008, European urology.

[16]  E. Diamandis,et al.  Functional Roles of Human Kallikrein-related Peptidases* , 2009, The Journal of Biological Chemistry.

[17]  J. Clements,et al.  Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  I Mehdi,et al.  Early detection of prostate cancer. , 1998, JPMA. The Journal of the Pakistan Medical Association.

[19]  H. Lilja,et al.  Prostate kallikrein markers in diagnosis, risk stratification and prognosis , 2009, Nature Reviews Urology.

[20]  E. Lianidou,et al.  Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Xiao-wen He,et al.  Over-expression of human kallikrein 11 is associated with poor prognosis in patients with low rectal carcinoma , 2010, Medical oncology.

[22]  J. Foekens,et al.  Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance , 2002, British Journal of Cancer.

[23]  E. Diamandis,et al.  Differential N-glycosylation of Kallikrein 6 Derived from Ovarian Cancer Cells or the Central Nervous System* , 2009, Molecular & Cellular Proteomics.

[24]  A. Scorilas,et al.  Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact , 2012, Tumor Biology.

[25]  A. Scorilas,et al.  Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11 , 2009, Thrombosis and Haemostasis.

[26]  D. Katsaros,et al.  Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma , 2003, International journal of cancer.

[27]  W. Catalona,et al.  The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. , 1999, Clinical chemistry.

[28]  G. Yousef,et al.  Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. , 2000, Biochemical and biophysical research communications.

[29]  D. Katsaros,et al.  A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy , 2007, Clinical Cancer Research.

[30]  G. Yousef,et al.  Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications , 2010, Biological chemistry.

[31]  E. Diamandis,et al.  Human tissue kallikrein gene family: applications in cancer. , 2005, Cancer letters.

[32]  E. Diamandis,et al.  Human tissue kallikreins: physiologic roles and applications in cancer. , 2004, Molecular cancer research : MCR.

[33]  H. Lilja,et al.  Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA. , 1996, Cancer treatment and research.

[34]  A. Scorilas,et al.  Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia , 2010, Cancer science.

[35]  E. Diamandis,et al.  The emerging roles of human tissue kallikreins in cancer , 2004, Nature Reviews Cancer.

[36]  E. Diamandis,et al.  Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung , 2008, Biological chemistry.

[37]  B. G. Blijenberg,et al.  hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. , 2007, European urology.

[38]  A. Scorilas,et al.  The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer , 2009, British Journal of Cancer.

[39]  M. Zheng,et al.  Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer , 2006, Journal of gastroenterology and hepatology.